Fig. 6

MAPK3 was required for the protective effects of miR-483-5p inhibition against hypoxic cardiomyocytes. AC16 cells were co-transfected with miR-483-5p inhibitor and si-MAPK3 or si-NC, followed by 24 h hypoxia treatment. a Western blotting was performed to determine the protein expression of MAPK3. b Cell viability was measured using a CCK-8 assay. c and d Cell apoptosis was analyzed using flow cytometry with double Annexin V FITC-PI staining. e through g The content of MDA, the activities SOD and CAT were measured using commercial assay kits. Data are indicated as means ± SD of three independent experiments. **p < 0.01, ***p < 0.001, as compared with miR-483-5p inhibitor + si-NC